Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTB4R | Q15722 | 19/20 | 1.00 |
| ▸ | LTB4R2 | Q9NPC1 | 10/20 | 1.00 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.49 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1890696 | 1.00 | LTB4R (1.00) | LTB4RLTB4R2CYSLTR2CYSLTR1 | |
| SCHEMBL29354842 | 1.00 | LTB4R (1.00) | LTB4RLTB4R2CYSLTR2CYSLTR1 | |
| SCHEMBL29369941 | 1.00 | LTB4R (1.00) | LTB4RLTB4R2CYSLTR2CYSLTR1 | |
| SCHEMBL8941433 | 0.95 | LTB4R (0.91) | LTB4RLTB4R2CYSLTR2CYSLTR1 | |
| SCHEMBL8957158 | 0.92 | LTB4R (0.85) | LTB4RLTB4R2 | |
| SCHEMBL8941451 | 0.91 | LTB4R (0.84) | LTB4RLTB4R2CYSLTR2CYSLTR1 | |
| SCHEMBL8941328 | 0.91 | LTB4R (0.83) | LTB4RLTB4R2CYSLTR2CYSLTR1 | |
| SCHEMBL8941563 | 0.88 | LTB4R (1.00) | LTB4RLTB4R2 | |
| SCHEMBL8957249 | 0.87 | LTB4R (0.77) | LTB4RLTB4R2 | |
| SCHEMBL5694677 | 0.86 | LTB4R (0.76) | LTB4RLTB4R2CYSLTR2CYSLTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110105959-A1 | Novel Methods for Bone Treatment by Modulating an Arachidonic Acid Metabolic or Signaling Pathway | ACCELALOX, INC. (US) | 2011-05-05 | — | — | US | claimed |
| WO-2009105723-A2 | NOVEL METHODS FOR BONE TREATMENT BY MODULATING AN ARACHIDONIC ACID METABOLIC OR SIGNALING PATHWAY | ACCELALOX, INC. (US) | 2009-08-27 | — | — | WO | claimed |
| WO-2001034199-A2 | ONCOLYTIC COMBINATIONS FOR THE TREATMENT OF CANCER | ELI LILLY AND COMPANY (US) | 2001-05-17 | — | — | WO | claimed |
| US-20160166508-A1 | Method and Composition for Treating Inflammatory Disorders | MEDA AB (SE) | 2016-06-16 | — | — | US | disclosed |
| US-20160166508-A1 | Method and Composition for Treating Inflammatory Disorders | MEDA AB (SE) | 2016-06-16 | — | — | US | disclosed |
| EP-2301562-B1 | Irrigation solution and method for inhibition of pain, inflammation and spasm | OMEROS CORP (US) | 2013-04-17 | — | — | EP | disclosed |
| EP-1609477-B1 | Irrigation solution and use thereof for the perioperative inhibition of pain/inflammation and/or spasm at a vascular structure | OMEROS CORP (US) | 2011-11-09 | — | — | EP | disclosed |
| US-20110105959-A1 | Novel Methods for Bone Treatment by Modulating an Arachidonic Acid Metabolic or Signaling Pathway | ACCELALOX, INC. (US) | 2011-05-05 | — | — | US | disclosed |
| EP-2301562-A1 | Irrigation solution and method for inhibition of pain, inflammation and spasm | Omeros Corporation (US) | 2011-03-30 | — | — | EP | disclosed |
| US-20090280153-A1 | electrical devices, anti-scarring agents, and therapeutic compositions | ANGIOTECH INTERNATIONAL AG (CH) | 2009-11-12 | — | — | US | disclosed |
| US-20090226500-A1 | SUTURES AND ANTI-SCARRING AGENTS | ANGIOTECH PHARMACEUTICALS, INC (CA) | 2009-09-10 | — | — | US | disclosed |
| WO-2006121522-A2 | IMPLANTABLE SENSORS AND PUMPS, ANTI-SCARRING AGENTS, AND THERAPEUTIC COMPOSITIONS | ANGIOTECH INTERNATIONAL AG (CH) | 2006-11-16 | — | — | WO | disclosed |
| WO-2006121518-A2 | ELECTRICAL DEVICES, ANTI-SCARRING AGENTS, AND THERAPEUTIC COMPOSITIONS | ANGIOTECH INTERNATIONAL AG (CH) | 2006-11-16 | — | — | WO | disclosed |
| EP-1609477-A1 | Irrigation solution and use thereof for the perioperative inhibition of pain/inflammation and/or spasm at a vascular structure | Omeros Corporation (US) | 2005-12-28 | — | — | EP | disclosed |
| EP-0799051-B1 | IRRIGATION SOLUTION AND USE THEREOF FOR PERIOPERATIVELY INHIBITING PAIN, INFLAMMATION AND SPASM AT A WOUND | OMEROS CORP (US) | 2005-07-27 | — | — | EP | disclosed |
| WO-2001034133-A2 | ONCOLYTIC COMBINATIONS FOR THE TREATMENT OF CANCER | ELI LILLY AND COMPANY (US) | 2001-05-17 | — | — | WO | disclosed |
| WO-2001034134-A2 | ONCOLYTIC COMBINATIONS FOR THE TREATMENT OF CANCER | ELI LILLY AND COMPANY (US) | 2001-05-17 | — | — | WO | disclosed |
| WO-2001034199-A2 | ONCOLYTIC COMBINATIONS FOR THE TREATMENT OF CANCER | ELI LILLY AND COMPANY (US) | 2001-05-17 | — | — | WO | disclosed |
| EP-0799051-A2 | IRRIGATION SOLUTION AND METHOD FOR INHIBITION OF PAIN, INFLAMMATION AND SPASM | OMEROS MEDICAL SYSTEMS, INC (US) | 1997-10-08 | — | — | EP | disclosed |
| WO-1996019233-A2 | IRRIGATION SOLUTION AND METHOD FOR INHIBITION OF PAIN, INFLAMMATION AND SPASM | OMEROS MEDICAL SYSTEMS, INC. (US) | 1996-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090226500-A1 | SUTURES AND ANTI-SCARRING AGENTS | COL1A1, COL2A1, COL14A1 | LTB4R 374/4885LTB4R2 326/4885CYSLTR2 520/4885 |
| US-20160166508-A1 | Method and Composition for Treating Inflammatory Disorders | LIPA, HRH2, HRH1 | LTB4R 8/4885LTB4R2 7/4885CYSLTR2 9/4885 |
| US-20090280153-A1 | electrical devices, anti-scarring agents, and therapeutic compositions | GAP43, TNNC1, GJB2 | LTB4R 352/4885LTB4R2 348/4885CYSLTR2 313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.